Trial Profile
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; B-cell lymphoma; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ECHO-202; KEYNOTE-037
- Sponsors Incyte Corporation
- 29 Jan 2021 Status changed from active, no longer recruiting to completed.
- 24 Sep 2020 Planned End Date changed from 1 Aug 2020 to 6 Nov 2020.
- 17 Dec 2019 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.